In 2025, the UK pharmaceutical sector remains a critical component of the life sciences economy, valued for its R&D strength, skilled workforce and innovative medicine pipeline. However, the industry faces headwinds from declining investment, growing regulatory burdens and increasing NHS payment demands.
CLICK HERE TO DOWNLOAD UK Pharmaceuticals (1)
